Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease 
BlueScope Steel Announces A$1 Special Dividend After Asset Sales 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
AFT Leaves X Over AI-Generated Images of Minors 
Tesla, EEOC Move Toward Mediation in Racial Harassment Lawsuit 
U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
Alphabet Stock Poised for Growth as Bank of America Sees Strong AI Momentum Into 2026 
KING OF PRUSSIA, Pa., March 29, 2017 -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will be presenting at Needham & Company’s 16th Annual Healthcare Conference on Wednesday, April 5, 2017 at 10:00 a.m. EDT in New York.
To join a live audio webcast of the presentation, please visit the Investor section of the Company’s website. Following the conclusion of the presentation, the webcast will be available for replay for 30 days.
About Trevena
Trevena, Inc. is a biopharmaceutical company developing innovative therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The Company has discovered four novel and differentiated drug candidates, including OLINVO™ (oliceridine injection). Trevena also has discovered TRV250, in preclinical development for the treatment of migraine, and TRV734, for pain. The Company is actively working on an early stage portfolio of drug discovery programs.
Contacts Trevena, Inc. Investors: Jonathan Violin, Ph.D. Sr. Director, Investor Relations 610-354-8840 x231 [email protected] or Media: Public Relations [email protected]
